Khiron Life Sciences, a medical cannabis provider, completed the acquisition of Pharmadrug Production, a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients, from Pharmadrug, a pharmaceutical company. Financial terms were not disclosed. "We are very pleased that we have now received all the necessary permits and licenses in connection with the acquisition and integration of the Target and that we can continue our growth course in Europe on an expedited pace with full control over the value chain up to the pharmacy. We are very excited to take advantage of the Target's excellent infrastructure and experienced team, which will enrich us professional and personally," Franziska Katterbach, Khiron President.